

Neurology®

The most widely read and highly cited peer-reviewed neurology journal
The Official Journal of the American Academy of Neurology



Neurology Publish Ahead of Print
DOI: 10.1212/WNL.0000000000201537

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Author(s):

João Pedro Marto, MD¹; Davide Strambo, MD²; George Ntaios, MD³; Thanh N. Nguyen, MD, FRCP⁴; Roman Herzig, MD, PhD⁵; Anna Czlonkowska, MD, PhD⁶; Jelle Demeestere, MD⁷; Ossama Yassin Mansour, MD, PhD⁸; Alexander Salerno, MD²; Susanne Wegener, MD⁹; Philipp Baumgartner, MD⁹; Carlo W Cereda, MD¹⁰; Giovanni Bianco, MD¹⁰; Morin Beyeler, MD¹¹; Marcel Arnold, MD¹¹; Emmanuel Carrera, MD¹²; Paolo Machi, MD¹³; Valerian Altersberger, MD¹⁴; Leo Bonati, MD¹⁴; Henrik Gensicke, MD¹⁴; Manuel Bolognese, MD¹⁵; Nils Peters, MD¹⁶; Stephan Wetzel, MD¹⁶; Marta Magriço, MD¹; João Nuno Ramos, MD¹⁷; João Sargento-Freitas, MD¹⁸; Rita Machado, MD¹⁸; Carolina Maia, MD¹⁸; Egídio Machado, MD¹⁹; Ana Paiva Nunes, MD²⁰; Patricia Ferreira, MD²⁰; Teresa Pinho e Melo, MD²¹; Mariana Carvalho Dias, MD²¹; André Paula, MD²¹; Manuel Alberto Correia, MD²²; Pedro Castro, MD, PhD²³; Elsa Azevedo, MD PhD²³; Luís Albuquerque, MD²⁴; José Nuno Alves, MD²⁵; Joana Ferreira-Pinto, MD²⁵; Torcato Meira, MD²⁶; Liliana Pereira, MD²⁷; Miguel Rodrigues, MD²⁷; Andre Pinho Araujo, MD²⁸; Marta Rodrigues, MD²⁸; Mariana Rocha, MD²⁹; Ângelo Pereira-Fonseca, MD³⁰; Luís Ribeiro, MD³⁰; Ricardo Varela, MD³¹; Sofia Malheiro, MD³¹; Manuel Cappellari, MD³²; Cecilia Zivelonghi, MD³²; Giulia Sajeve, MD³²; Andrea Zini³³; mauro gentile, MD³³; Stefano Forlivesi³³; Ludovica Migliaccio, MD³³; Maria Sessa, MD³⁴; Sara La Gioia, MD³⁴; Alessandro Pezzini, MD³⁵; Davide Sangalli, MD³⁶; Marialuisa Zedde, MD³⁷; Rosario Pascarella, MD³⁸; Carlo Ferrarese, MD, PhD³⁹; Simone Beretta, MD³⁹; Susanna Diamanti, MD³⁹; Ghil Schwarz, MD⁴⁰; Giovanni Frisullo, MD⁴¹; Simona Marcheselli, MD⁴²; Pierre Seners, MD⁴³; Candice Sabben, MD⁴³; Simon Escalard, MD⁴³; Michel Piotin, MD, PhD⁴⁴; Benjamin Maier, MD, MSc⁴⁴; Guillaume Charbonnier, MD⁴⁵; Fabrice Vuillier, MD⁴⁵; Loïc Legris⁴⁶; Pauline Cuisenier, MD⁴⁶; Francesca R Vodret, MD⁴⁶; Gaultier Marnat, MD⁴⁷; Jean-Sebastien Liegey, MD⁴⁷; Igor Sibon, MD, PhD⁴⁷; Fabian Flottmann, MD⁴⁸; Gabriel Broocks, MD⁴⁸; Nils-Ole Gloyer, MD⁴⁸; Ferdinand O. Bohmann, MD⁴⁹; Jan Hendrik Schaefer, MD⁴⁹; Christian Nolte⁵⁰; Heinrich J. Audebert, MD⁵⁰; Eberhard Siebert, MD⁵¹; Marek Sykora, MD⁵²; Wilfried Lang, MD⁵²; Julia Ferrari, MD⁵²; Lukas Mayer-Suess, MD⁵³; Michael Knoflach, MD⁵³; Elke Ruth Gizewski, MD⁵⁴; Jeffrey Stolp, MD⁵⁵; Lotte J Stolze, MD⁵⁵; Jonathan M. Coutinho, MD, PhD⁵⁵; Paul Nederkoorn, MD PhD⁵⁵; Ido van den Wijngaard, MD, PhD⁵⁶; Joke De Meris, MD⁵⁶; Robin Lemmens, MD⁵⁷; Sylvie De Raedt, MD PhD⁵⁷; Fenne Vandervorst, MD⁵⁷; Matthieu Pierre Rutgers, MD⁵⁸; Antoine Guilmot, MD⁵⁸; Anne Dusart, MD⁵⁹; Flavio Bellante, MD⁵⁹; Patricia Calleja-Castaño, MD⁶⁰; Fernando Ostos, MD⁶⁰; Guillermo González-Ortega, MD⁶⁰; Paloma Martín-Jiménez, MD⁶⁰; Sebastian García-Madróna, MD⁶¹; Antonio Cruz-Culebras, MD⁶¹; Rocio Vera, MD⁶¹; Maria Consuelo Matute, MD⁶¹; Blanca Fuentes, MD⁶²; María Alonso-de-Leciñana, MD⁶²; Ricardo Rigual, MD⁶²; Exuperio Díez-Tejedor, MD⁶²; Soledad Perez-Sanchez, MD⁶³; Joan Montaner, MD, PhD⁶³; Fernando Díaz-Otero, MD⁶⁴; Natalia Pérez-de-la-Ossa, MD⁶⁵; Belén Flores-Pina, MD⁶⁵; Lucia Muñoz-Narbona, MD⁶⁵; Angel Chamorro, MD, PhD⁶⁶; Alejandro Rodríguez-Vázquez, MD⁶⁶; Arturo Renú, MD, PhD⁶⁶; Oscar Ayo-Martin, MD, PhD⁶⁷; Francisco Hernández-Fernández, MD, PhD⁶⁷; Tomas Segura, MD⁶⁷; Herbert Tejada-Meza, MD⁶⁸; Daniel Sagarra-Mur, MD⁶⁹; Marta Serrano-Ponz, MD⁶⁹; Thant Hlaing, MD⁷⁰; Isaiah See, MD⁷¹; Robert Simister, MD⁷¹; David Werring, FRCP, PhD⁷²; Espen

Saxhaug Kristoffersen, MD, PhD⁷³; Annika Nordanstig, MD, PhD⁷⁴; Katarina Jood, MD⁷⁴; Alexandros Rentzos, MD⁷⁵; Libor Šimůnek, MD⁵; Dagmar Krajíčková, MD⁵; Antonín Krajina, MD⁷⁶; Robert Mikulik, MD, PhD⁷⁷; Martina Cvíková, MD⁷⁷; Jan Vinklár, MD⁷⁷; David Školoudík, MD⁷⁸; Martin Roubec, MD⁷⁸; Eva Hurtiková, MD⁷⁸; Rostislav Hrubý, MD⁷⁹; Svatopluk Ostry, MD⁷⁹; Ondřej Skoda, MD⁸⁰; Marek Pernicka, MD⁸⁰; Lubomir Jurak, MD, PhD⁸¹; Zuzana Eichlová, MD⁸¹; Martin Jíra, MD⁸¹; Martin Kovar, MD⁸²; Michal Panský, MD⁸²; Pavel Mencl, MD⁸²; Hana Palouskova, MD⁸³; Aleš Tomek, MD⁸⁴; Petr Janský, MD⁸⁴; Anna Olšerová, MD⁸⁴; Martin Sramek, MD⁸⁵; Roman Havlíček, MD⁸⁵; Petr Malý, MD⁸⁵; Lukáš Trakal, MD⁸⁵; Jan Fiksa, MD⁸⁶; Matěj Slovák, MD⁸⁶; Michal Adam Karlinski, MD, PhD⁶; Maciej Nowak, MD⁶; Halina Sienkiewicz-Jarosz, MD⁸⁷; Anna Bochynska, MD⁸⁷; Pawel Wrona, MD⁸⁸; Tomasz Homa, MD⁸⁸; Katarzyna Sawczynska, MD⁸⁸; Agnieszka Slowik, MD, PhD⁸⁸; Ewa Wlodarczyk, MD⁸⁸; Marcin Wiacek, MD⁸⁹; Izabella Tomaszewska-Lampart, MD⁸⁹; Bartosz Sieczkowski, MD⁸⁹; Halina Bartosik-Psujek, MD⁸⁹; Marta Bilik, MD⁹⁰; Anna Bandzarewicz, MD⁹⁰; Malgorzata Dorobek, MD, PhD⁹¹; Justyna Zielinska-Turek, MD⁹¹; Marta Nowakowska-Kotas, MD⁹²; Krystian Obara, MD⁹²; Paweł Urbanowski, MD⁹²; Sławomir Budrewicz, MD⁹²; Maciej Guziński, MD⁹³; Milena Świtońska, MD⁹⁴; Iwona Rutkowska, MD⁹⁵; Paulina Sobieszak-Skura, MD⁹⁵; Beata M. Labuz-Roszak, MD, PhD⁹⁶; Aleksander Debiec, MD⁹⁷; Jacek Staszewski, MD⁹⁷; Adam Stępień, MD⁹⁷; Jacek Zwiernik, MD⁹⁸; Grzegorz Wasilewski, MD⁹⁹; Cristina Tiu, MD¹⁰⁰; Elena Oana Terecoasă, MD¹⁰⁰; Razvan Alexandru Radu, MD¹⁰⁰; Anca Negrița, MD¹⁰⁰; Bogdan Dorobat, MD¹⁰¹; Cristina Panea, MD¹⁰²; Vlad Tiu, MD¹⁰²; Simona Petrescu, MD¹⁰²; Atilla Ozdemir, MD¹⁰³; Mostafa Mahmoud, MD¹⁰⁴; Hussam El-Samahy, MD¹⁰⁴; Hazem Abdelkhalik, MD¹⁰⁵; Jasem Al-Hashel, MD¹⁰⁶; Ismail Ibrahim Ismail, MD¹⁰⁷; Athari Salmeen, MD¹⁰⁷; Abdoreza Ghoreishi, MD¹⁰⁸; Sergiu Ionut Sabetay, MD¹⁰⁹; Hana Gross, MD⁴; Piers Klein⁴; Mohamad Abdalkader, MD⁴; Pascal Jabbour, MD¹¹⁰; Kareem El Naamani, MD¹¹⁰; Stavropoula Tjoumakaris, MD¹¹⁰; Rawad Abbas, MD¹¹⁰; Ghada A. Mohamed, MD¹¹¹; Alex Chebl, MD¹¹²; Jiangyong Min, MD¹¹³; Majesta Hovingh, MD¹¹³; Jenney P Tsai, MD¹¹³; Muhib Khan, MD¹¹³; Krishna Nalleballe, MD¹¹⁴; Sanjeeva Onteddu, MD¹¹⁴; Hesham Masoud, MD¹¹⁵; Mina Michael, MD¹¹⁵; Navreet Kaur, MD¹¹⁵; Laith Maali, MD¹¹⁶; Michael G Abraham, MD¹¹⁶; Priyank Khandelwal, MD¹¹⁷; Ivo Bach, MD¹¹⁷; Melody Ong, MD¹¹⁷; Denis Babici, MD¹¹⁷; Ayaz M. Khawaja, MD¹¹⁸; Maryam Hakemi, BSN, MS, AGNP¹¹⁸; Kumar Rajamani, MD¹¹⁸; Vanessa Cano-Nigenda, MD¹¹⁹; Antonio Arauz, MD, PhD¹¹⁹; Pablo Amaya, MD¹²⁰; Natalia Llanos, MD¹²¹; Akemi Arango, MD¹²¹; Miguel Ángel Vences, MD¹²²; Jose Dominguo Barrientos Guerra, MD¹²³; Rayllene Caetano, MD¹²⁴; Rodrigo Targa Martins, MD¹²⁴; Sergio Daniel Scollo, MD¹²⁵; Patrick Matic Yalung, MD¹²⁶; Shashank Nagendra, MD¹²⁷; Abhijit Gaikwad, MD¹²⁷; Kwon-Duk Seo, MD¹²⁸; Georgios Georgiopoulos, MD^{129,130}; Raul G Nogueira, MD¹¹¹; Patrik Michel, M.D., Ph.D² on behalf of and the Global COVID-19 Stroke Registry

Corresponding author

João Pedro Marto, MD

Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa

Ocidental, Lisbon, Portugal

Rua da Junqueira nº 126, 1349-019, Lisbon, Portugal

Telephone: 00351210432181

Email: joao.pedro.seabra.marto@gmail.com

Affiliation Information for All Authors: 1. Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; 2. Stroke Centre, Neurology Service, Department of Neurological Sciences, Lausanne University Hospital, Lausanne, Switzerland; 3. Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece; 4. Department of Neurology, Radiology, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA; 5. Department of Neurology, Comprehensive Stroke Centre, Charles University Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic; 6. 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland; 7. Neurology Department, Leuven University Hospital, Leuven, Belgium; 8. Alexandria University Hospitals and Affiliated Stroke Network, Alexandria, Egypt; 9. Department of Neurology, University Hospital of Zurich, Zurich, Switzerland; 10. Stroke Center, Neurocenter of Southern Switzerland, EOC, Lugano, Switzerland; 11. Stroke Center, Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Switzerland; 12. Stroke Centre, Geneva University Hospital, Geneva, Switzerland; 13. Department of Neuroradiology, Geneva University Hospital, Geneva, Switzerland; 14. Stroke Centre, University Hospital Basel and University of Basel, Switzerland; 15. Stroke Centre, Kantonsspital Lucerne, Switzerland; 16. Stroke Centre, Hirslanden Hospital, Zurich, Switzerland; 17. Department of Neuroradiology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; 18. Department of Neurology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal; 19. Department of Neuroradiology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal; 20. Stroke Unit, Hospital de São José, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal; 21. Stroke Unit, Department of Neurology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; 22. Department of Neuroradiology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; 23. Department of Neurology, Centro Hospitalar Universitário São João, Porto, Portugal; 24. Department of Neuroradiology, Centro Hospitalar Universitário São João, Porto, Portugal; 25. Department of Neurology, Hospital de Braga, Braga, Portugal; 26. Department of Neuroradiology, Hospital de Braga, Braga, Portugal; 27. Department of Neurology, Hospital Garcia de Orta, Almada, Portugal; 28. Department of Neuroradiology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal; 29. Department of Neurology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal; 30. Department of Neurology, Unidade Local de Saúde de Matosinhos, Matosinhos, Portugal; 31. Department of Neurology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 32. Stroke Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; 33.

IRCCS Istituto delle Scienze Neurologiche di Bologna, Department of Neurology and Stroke Centre, Maggiore Hospital, Bologna, Italy; 34. Department of Neurology, ASST Papa Giovanni XXIII, Bergamo, Italy; 35. Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Brescia, Italy; 36. Department of Neurology and Stroke Unit, Azienda Socio Sanitaria Territoriale, Lecco, Italy; 37. Neurology Unit, Stroke Unit, Azienda Unità Sanitaria-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 38. Neuroradiology Unit, Azienda Unità Sanitaria-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 39. Department of Neurology, San Gerardo Hospital, Department of Medicine and Surgery and Milan Centre for Neuroscience, University of Milano Bicocca, Monza, Italy; 40. Stroke Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; 41. Department of Neurology, Policlinico Universitario Agostino Gemelli, Rome, Italy; 42. Emergency Neurology and Stroke Unit, IRCCS Humanitas Clinical and Research Center, Rozzano, Italy; 43. Department of Neurology, Hôpital Fondation A. de Rothschild, Paris, France; 44. Department of Interventional Neuroradiology, Hôpital Fondation A. de Rothschild, Paris, France; 45. Department of Interventional Neuroradiology, Centre Hospitalier Régional Universitaire, Hôpital Jean Minjoz, Besançon, France; 46. Neurology, Stroke Unit, Centre Hospitalier Universitaire, Grenoble Alpes, France; 47. Department of Interventional and Diagnostic Neuroradiology, Bordeaux University Hospital, Bordeaux, France; 48. Department of Diagnostic and Interventional Neuroradiology, University Medical Center-Hamburg-Eppendorf, Germany; 49. Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; 50. Department of Neurology and Centre for Stroke Research, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Germany; 51. Department of Neuroradiology, Charité-Universitätsmedizin Berlin, Germany; 52. Department of Neurology, St. John's Hospital, Vienna, Austria; 53. Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria; 54. Department of Neuroradiology, Medical University of Innsbruck, Innsbruck, Austria; 55. Department of Neurology, Amsterdam University Medical Centers, Amsterdam, Netherlands; 56. Department of Neurology, Haaglanden Medical Centre, Hague and Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; 57. Department of Neurology, Universitair Ziekenhuis Brussel, Centre for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium; 58. Department of Neurology, Stroke Unit, Europe Hospitals, Brussels, Belgium; 59. Department of Neurology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium; 60. Department of Neurology and Stroke Centre, Hospital Universitario 12 de Octubre. Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; 61. Department of Neurology and Stroke Centre, Hospital Universitario Ramón y Cajal, Ramon y Cajal Institute for Health Research (IRYCIS), Madrid, Spain; 62. Department of Neurology and Stroke Centre. Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain; 63. Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain; 64. Stroke Centre, Hospital General Universitario Gregorio Marañón, Madrid, Spain; 65. Stroke Unit, Germans Trias Hospital, Barcelona, Spain; 66. Department of Neurology, Comprehensive Stroke Centre, Hospital Clinic from Barcelona, Barcelona, Spain; 67. Department of Neurology,

Complejo Hospitalario Universitario de Albacete, Albacete; 68. Stroke Unit, Department of Neurology, and Interventional Neuroradiology Unit, Hospital Universitario Miguel Servet, Spain; 69. Stroke Unit, Department of Neurology, Hospital Universitario Miguel Servet, Spain; 70. Stroke and Geriatric Medicine, Aintree University Hospital, United Kingdom; 71. Comprehensive Stroke Service, University College London Hospitals NHS Foundation Trust and Stroke Research Centre, University College London, United Kingdom.; 72. University College London, Queen Square Institute of Neurology, London, United Kingdom; 73. Department of Neurology, Akershus University Hospital, Lørenskog and Department of General Practice, University of Oslo, Norway; 74. Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden. 75. Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg and Department of Interventional and Diagnostic Neuroradiology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden; 76. Department of Radiology, Comprehensive Stroke Centre, Charles University Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic; 77. International Clinical Research Centre and Department of Neurology, St. Anne's University Hospital and Faculty of Medicine at Masaryk University, Brno, Czech Republic; 78. Center for Health Research, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; 79. Department of Neurology, České Budějovice Hospital, České Budějovice, Czech Republic; 80. Department of Neurology, Jihlava Hospital, Jihlava, Czech Republic; 81. Neurocenter, Regional Hospital Liberec, Liberec, Czech Republic; 82. Cerebrovascular Centre, Na Homolce Hospital, Prague, Czech Republic; 83. Department of Neurology, Karviná Miners Hospital Inc., Karviná, Czech Republic; 84. Cerebrovascular Centre, University Hospital in Motol, Prague, Czech Republic; 85. Cerebrovascular Centre, Central Military Hospital, Prague, Czech Republic; 86. Cerebrovascular Centre, General University Hospital, Prague, Czech Republic; 87. 1st Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland; 88. Department of Neurology, University Hospital, Jagiellonian University, Cracow, Poland; 89. Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Poland; 90. Department of Neurology and Stroke, St. John Paul II Western Hospital, Grodzisk Mazowiecki, Poland; 91. Department of Neurology, Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland; 92. Department of Neurology, Wrocław Medical University, Wrocław, Poland; 93. Department of Radiology, Wrocław Medical University, Wrocław, Poland; 94. Department of Neurosurgery and Neurology, Nicolaus Copernicus University in Torun Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland; 95. Stroke Intervention Centre, Department of Neurosurgery and Neurology, Jan Biziel University Hospital, Bydgoszcz, Poland; 96. Department of Neurology, Institute of Medical Sciences, University of Opole, Poland; 97. Clinic of Neurology, Military Institute of Medicine, Warsaw, Poland; 98. Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland; 99. Department of Radiology, Provincial Specialist Hospital, Olsztyn, Poland; 100. Department of Neurology,

University Emergency Hospital Bucharest, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania; 101. Department of Radiology, University Emergency Hospital Bucharest, Bucharest, Romania; 102. Department of Neurology and Stroke Unit, Elias University Emergency Hospital, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania; 103. Department of Neurology, Eskisehir Osmangazi University, Eskisehir, Turkey; 104. Ain Shams University Affiliated Saudi German Hospital, Egypt; 105. Neuropsychiatry Department, Tanta University, Egypt; 106. Department of Neurology, Ibn Sina Hospital, Kuwait; 107. Department of Neurology, Jaber Al-Ahmad Hospital, Kuwait; 108. Department of Neurology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; 109. Stroke Unit, Neurology Department, Hillel Yaffe Medical Center, Hadera, Israel; 110. Department of Neurosurgery, Thomas Jefferson University Hospital, PA, USA; 111. Departments of Radiology, Neurology and Neurosurgery, Grady Memorial Hospital, Atlanta, GA, USA; 112. Department of Neurology, Henry Ford Hospital, Detroit, MI, USA; 113. Comprehensive Stroke Centre and Department of Neurosciences, Spectrum Health and Michigan State University, MI, USA; 114. Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 115. Department of Neurology, Upstate University Hospital, NY, USA; 116. Department of Neurology, University of Kansas Medical Centre, KS, USA; 117. Endovascular Neurological Surgery & Neurology, Rutgers, The State University of New Jersey, Newark, NJ, USA; 118. Department of Neurology, Wayne State University, Detroit Medical Center, Detroit, MI, USA; 119. Stroke Clinic, Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico City, Mexico; 120. Department of Neurology, Fundación Valle del Lili, Cali, Colombia; 121. Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia; 122. Department of Neurology, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú; 123. Hospital General San Juan de Dios, Guatemala, Guatemala; 124. Department of Neurology, Hospital Nossa Senhora da Conceição Hospital, Porto Alegre, Brazil; 125. Ramos Mejía Hospital, Stroke Unit, Buenos Aires, Argentina; 126. St. Luke's Medical Center, Global City, Philippines; 127. Department of Neurology, Grant Medical College and Sir JJ Hospital, Mumbai, India; 128. Department of Neurology, National Health Insurance Service Ilsan Hospital, Goyang, Korea; 129. School of Biomedical Engineering and Imaging Sciences, St Thomas Hospital, King's College London, UK; 130. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece

Equal Author Contribution:

João Pedro Marto and Davide Strambo contributed equally

Contributions:

João Pedro Marto: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Davide Strambo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

George Ntaios: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Thanh N. Nguyen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Roman Herzig: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Anna Czlonkowska: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jelle Demeestere: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ossama Yassin Mansour: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Alexander Salerno: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Susanne Wegener: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Philipp Baumgartner: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Carlo W Cereda: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Giovanni Bianco: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Morin Beyeler: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marcel Arnold: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Emmanuel Carrera: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Paolo Machi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Valerian Altersberger: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Leo Bonati: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Henrik Gensicke: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Manuel Bolognese: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Nils Peters: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Stephan Wetzel: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marta Magriço: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

João Nuno Ramos: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

João Sargento-Freitas: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Rita Machado: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Carolina Maia: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Egídio Machado: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ana Paiva Nunes: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Patricia Ferreira: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Teresa Pinho e Melo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Mariana Carvalho Dias: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

André Paula: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Manuel Alberto Correia: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Pedro Castro: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Elsa Azevedo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Luís Albuquerque: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

José Nuno Alves: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Joana Ferreira-Pinto: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Torcato Meira: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Liliana Pereira: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Miguel Rodrigues: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Andre Pinho Araujo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marta Rodrigues: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Mariana Rocha: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ângelo Pereira-Fonseca: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Luís Ribeiro: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ricardo Varela: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sofia Malheiro: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Manuel Cappellari: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Cecilia Zivelonghi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Giulia Sajeve: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Andrea Zini: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

mauro gentile: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Stefano Forlivesi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ludovica Migliaccio: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Maria Sessa: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sara La Gioia: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Alessandro Pezzini: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Davide Sangalli: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marialuisa Zedde: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Rosario Pascarella: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Carlo Ferrarese: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Simone Beretta: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Susanna Diamanti: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ghil Schwarz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Giovanni Frisullo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Simona Marcheselli: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Pierre Seners: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Candice Sabben: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Simon Escalard: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Michel Plotin: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Benjamin Maïer: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Guillaume Charbonnier: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Fabrice Vuillier: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Loïc Legris: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Pauline Cuisenier: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Francesca R Vodret: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Gaultier Marnat: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jean-Sebastien Liegey: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Igor Sibon: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Fabian Flottmann: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Gabriel Broocks: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Nils-Ole Gloyer: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ferdinand O. Bohmann: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jan Hendrik Schaefer: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Christian Nolte: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Heinrich J. Audebert: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Eberhard Siebert: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marek Sykora: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Wilfried Lang: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Julia Ferrari: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Lukas Mayer-Suess: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Michael Knoflach: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Elke Ruth Gizewski: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jeffrey Stolp: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Lotte J Stolze: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jonathan M. Coutinho: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Paul Nederkoorn: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ido van den Wijngaard: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Joke De Meris: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Robin Lemmens: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sylvie De Raedt: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Fenne Vandervorst: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Matthieu Pierre Rutgers: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Antoine Guilmot: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Anne Dusart: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Flavio Bellante: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Patricia Calleja-Castaño: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Fernando Ostos: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Guillermo González-Ortega: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Paloma Martín-Jiménez: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sebastian García-Madróna: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Antonio Cruz-Culebras: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Rocio Vera: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Maria Consuelo Matute: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Blanca Fuentes: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

María Alonso-de-Leciñana: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ricardo Rigual: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Exuperio Díez-Tejedor: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Soledad Perez-Sanchez: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Joan Montaner: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Fernando Díaz-Otero: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Natalia Pérez-de-la-Ossa: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Belén Flores-Pina: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Lucia Muñoz-Narbona: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Angel Chamorro: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Alejandro Rodríguez-Vázquez: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Arturo Renú: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Oscar Ayo-Martin: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Francisco Hernández-Fernández: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Tomas Segura: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Herbert Tejada-Meza: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Daniel Sagarra-Mur: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marta Serrano-Ponz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Thant Hlaing: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Isaiah See: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Robert Simister: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

David Werring: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Espen Saxhaug Kristoffersen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Annika Nordanstig: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Katarina Jood: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Alexandros Rentzos: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Libor Šimůnek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Dagmar Krajčková: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Antonín Krajina: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Robert Mikulík: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Martina Cviková: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jan Vinklárek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

David Školoudík: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Martin Roubec: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Eva Hurtikova: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Rostislav Hrubý: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Svatopluk Ostry: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ondrej Skoda: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marek Pernicka: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Lubomir Jurak: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Zuzana Eichlová: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Martin Jíra: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Martin Kovar: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Michal Panský: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Pavel Mencl: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Hana Palouskova: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Aleš Tomek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Petr Janský: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Anna Olšerová: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Martin Sramek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Roman Havlicek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Petr Malý: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Lukáš Trkal: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jan Fiksa: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Matěj Slovák: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Michal Adam Karlinski: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Maciej Nowak: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Halina Sienkiewicz-Jarosz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Anna Bochynska: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Pawel Wrona: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Tomasz Homa: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Katarzyna Sawczynska: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Agnieszka Slowik: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ewa Włodarczyk: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marcin Wiacek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Izabella Tomaszewska-Lampart: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Bartosz Sieczkowski: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Halina Bartosik-Psujek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marta Bilik: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Anna Bandzarewicz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Malgorzata Dorobek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Justyna Zielinska-Turek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marta Nowakowska-Kotas: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Krystian Obara: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Paweł Urbanowski: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Slawomir Budrewicz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Maciej Guziński: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Milena Świtońska: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Iwona Rutkowska: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Paulina Sobieszak-Skura: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Beata M. Labuz-Roszak: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Aleksander Debiec: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jacek Staszewski: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Adam Stępień: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jacek Zwiernik: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Grzegorz Wasilewski: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Cristina Tiu: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Elena Oana Terecoasă: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Razvan Alexandru Radu: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Anca Negrița: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Bogdan Dorobat: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Cristina Panea: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Vlad Tiu: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Simona Petrescu: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Atila Ozdemir: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Mostafa Mahmoud: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Hussam El-Samahy: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Hazem Abdelkhalek: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jasem Al-Hashel: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ismail Ibrahim Ismail: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Athari Salmeen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Abdoreza Ghoreishi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sergiu Ionut Sabetay: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Hana Gross: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Piers Klein: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Mohamad Abdalkader: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Pascal Jabbour: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Kareem El Naamani: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Stavropoula Tjoumakaris: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Rawad Abbas: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ghada A. Mohamed: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Alex Chebl: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jiangyong Min: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Majesta Hovingh: Drafting/revision of the manuscript for content, including medical writing for content

Jenney P Tsai: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Muhib Khan: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Krishna Nalleballe: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sanjeeva Onteddu: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Hesham Masoud: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Mina Michael: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Navreet Kaur: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Laith Maali: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Michael G Abraham: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Priyank Khandelwal: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ivo Bach: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Melody Ong: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Denis Babici: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ayaz M. Khawaja: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Maryam Hakemi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Kumar Rajamani: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Vanessa Cano-Nigenda: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Antonio Arauz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Pablo Amaya: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Natalia Llanos: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Akemi Arango: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Miguel Ángel Vences: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jose Dominguo Barrientos Guerra: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Rayllene Caetano: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Rodrigo Targa Martins: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sergio Daniel Scollo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Patrick Matic Yalung: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Shashank Nagendra: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Abhijit Gaikwad: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Kwon-Duk Seo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Georgios Georgiopoulos: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Raul G Nogueira: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Patrik Michel: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Figure Count:

2

Table Count:

2

Search Terms:

[2] All Cerebrovascular disease/Stroke, [360] COVID-19, Intravenous thrombolysis, Mechanical thrombectomy, Outcomes

Acknowledgment:

We thank Melanie Price Hirt for English language correction and editing.

Study Funding:

Czech national stroke registry is supported by STROCZECH within CZECRIN Large Research Infrastructure (No. LM2018128) funded by the state budget of the Czech Republic.

Disclosures:

R. Herzig: Research grants from the Ministry of Health of the Czech Republic (grant number DRO – UHHK 00179906) and Charles University, Czech Republic (grant number PROGRES Q40); C. Nolte: Research grants from German Ministry of Research and Education, German Center for Neurodegenerative Diseases, German Center for cardiovascular Research. Speaker and/or advisory fees from Abbott, Alexion, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and Pfizer Pharma; S. Tjoumakaris: Advisory fees from Medtronic and MicroVention; J. Min: Advisory fees from Medtronic and Abbott; M. Khan: Research grants from National Institute of Health, Spectrum Health-Michigan State University Research Alliance and Genentech for research; P. Michel: Research grants from the Swiss National Science Foundation and Swiss Heart Foundation; All the other authors report no relevant disclosures.

Preprint DOI:

Received Date:

2022-04-27

Accepted Date:

2022-09-23

Handling Editor Statement:

Submitted and externally peer reviewed. The handling editor was José Merino, MD, MPhil, FAAN.

Abstract

Background and objectives

COVID-19 related inflammation, endothelial dysfunction and coagulopathy may increase the bleeding risk and lower efficacy of revascularization treatments in patients with acute ischemic stroke. We aimed to evaluate the safety and outcomes of revascularization treatments in patients with acute ischemic stroke and COVID-19.

Methods

Retrospective multicenter cohort study of consecutive patients with acute ischemic stroke receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021, tested for SARS-CoV-2 infection. With a doubly-robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT).

Results

Of a total of 15128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19. 5848 (38.7%) patients received IVT-only, and 9280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted odds ratio [OR] 1.53; 95% CI 1.16–2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20–2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23–1.99), 24-hour (OR 2.47; 95% CI 1.58–3.86) and 3-month mortality (OR 1.88; 95% CI 1.52–2.33).

COVID-19 patients also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26–1.60).

Discussion

Patients with acute ischemic stroke and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 treated patients. Current available data does not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in COVID-19 patients, or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring and establishing prognosis.

Introduction

Acute ischemic stroke (AIS) is a recognized complication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.¹ Inflammation, endothelial dysfunction and coagulopathy are the pathophysiological mechanisms involved in the

development of arterial thrombotic events.²⁻⁴

The Global COVID-19 Stroke Registry showed that patients with AIS and COVID-19 have a worse functional outcome than those without SARS-CoV-2 infection,⁵ which was later confirmed by other studies.⁶⁻¹⁰ Several hypotheses may explain these findings: 1) broad multisystem complications of COVID-19 such as acute respiratory distress syndrome, shock, secondary infection and pulmonary embolism;¹¹ 2) more severe ischemic strokes at admission;⁶⁻⁹ and 3) longer time to revascularization treatments.^{8,9}

Additionally, because of the above-mentioned mechanisms, the thrombo-inflammatory state, increased blood-brain barrier permeability and derangement of the fibrinolytic system identified in patients with COVID-19² may affect the safety and efficacy of intravenous thrombolysis (IVT) and endovascular treatment (EVT), and contribute to poorer outcomes.

Case series and cohort studies have shown the feasibility of revascularization treatments in patients with AIS and COVID-19. Some of these studies documented lower recanalization rates^{12,13} and higher rates of intracerebral hemorrhage¹³ in COVID-19 patients receiving endovascular treatment, but these studies were limited by the absence of a contemporary control group of non-COVID-19 patients, small sample size or lack of 3-month outcome assessment. For these reasons, the question of the safety and efficacy of revascularization treatments in acute stroke patients with COVID-19 remains unanswered.¹²⁻¹⁸

In this context, our aim was to assess safety and outcome of revascularization treatment in patients with AIS and COVID-19 in a large, multicenter, international cohort by comparison with a contemporary control group of non-COVID-19 patients with AIS from the same centers.

Methods

Study Design, Patient Selection and Study Variables

This was a retrospective, international, cohort study of consecutive AIS patients receiving IVT and/or EVT up to 24 hours from last time seen well, and according to each center's recommendations.

To participate in the study, each invited center needed to include at least one patient with COVID-19 and AIS treated with IVT and/or EVT. Patients were included from 1st of March 2020 to 30th of June 2021.

Patients with COVID-19 (exposed group) were defined as: 1) patients with community-acquired SARS-CoV-2 infection confirmed by a positive polymerase chain reaction (PCR) or antigen test, independent of the presence of COVID-19-related symptoms; 2) patients hospitalized due to COVID-19 with an in-hospital stroke; 3) patients with COVID-19-compatible symptoms before reperfusion treatment with positive PCR or antigen test within the first 7 days after treatment. Patients without COVID-19 (control group) were defined as patients without COVID-19-compatible symptoms and with a negative PCR or antigen test within the first 7 days after treatment.

The following exclusion criteria were used: 1) patients without a PCR or antigen test within the first 7 days after treatment; 2) patients with nosocomial SARS-CoV-2 infection after receiving revascularization treatments, defined as PCR or antigen tests becoming positive more than 7 days after treatment;¹⁹ 3) patients with a suspected/probable case of SARS-CoV-2 infection according to the World Health Organization definition;²⁰ 4) patients with symptomatic SARS-CoV-2 infection with symptoms resolution more than 7 days before treatment; 5) patients with asymptomatic SARS-

CoV-2 infection with treatment performed more than 10 days after the first positive test for SARS-CoV-2.

All study variables are detailed in the Supplement.

The reporting of this observational study is in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

Standard Protocol Approvals, Registrations, and Patient Consents

Participating centers were requested to anonymize their data before sending it to the coordinating center (Stroke Centre, Department of Neurology, Lausanne University Hospital, Lausanne, Switzerland). According to the local ethics committee regulations and national laws, each center was responsible for obtaining ethical approval for data collection and international data sharing. Informed consent was waived due to the retrospective nature of this study. This study was conducted according to the principles of the Declaration of Helsinki. In the coordinating center in Lausanne, Institutional Review Board approval and patient consent were not required according to the Swiss Federal Act on Research involving Human Beings from 2011 (HRA, Art. 3) as all data were anonymized and the project involved assessing safety and quality of routine AIS management in the participating centers. The study was registered under ClinicalTrials.gov identifier NCT04895462.

Data Availability

Anonymized data not published within this article will be made available by request from any qualified investigator.

Outcome Analysis

For the main outcome, we defined symptomatic intracerebral hemorrhage (SICH) according the ECASS-2 definition (≥ 4 -point worsening in NIHSS attributable to parenchymal hemorrhage).²¹ As secondary outcomes we defined: 1) symptomatic subarachnoid hemorrhage (SSAH) (≥ 4 -point worsening in NIHSS attributable to subarachnoid hemorrhage); 2) any symptomatic intracranial hemorrhage (SICH/SSAH) (combination of symptomatic intracerebral hemorrhage and symptomatic subarachnoid hemorrhage); 3) 24-hour mortality; 4) 3-month mortality; 5) 3-month mRS; 6) favorable 3-month outcome (mRS ≤ 2 or equal to pre-stroke mRS); 7) presence of any radiological hemorrhagic transformation; and 8) delta NIHSS at 24 hours (difference between admission NIHSS and NIHSS at 24 hours). If the patient was intubated, we considered the first NIHSS after extubation. For patients with extubation after 4 weeks or death before extubation, 24h NIHSS was quantified as 42; 9) recanalization after EVT measured by mTICI; 10) successful recanalization after EVT as final mTICI $\geq 2b$; 11) number of passes during EVT; and 12) first pass effect.²²

Statistical analysis

We summarized continuous variables as median values with interquartile range and categorical variables as absolute numbers and percentages. We compared baseline and outcome variables between the COVID-19 and control (without COVID-19) groups using the Pearson's chi-squared test for categorical variables and Mann-Whitney U tests for continuous variables, as appropriate. We performed all analyses outcomes in the entire cohort and in the two treatment subgroups, IVT-only and EVT.

To assess the association between COVID-19 and post-stroke outcomes we used doubly robust estimation, which offers more robustness than a single model approach of

exposure or outcome modelling.²³ In detail, we calculated a doubly robust estimator of COVID-19 effect for each outcome of interest combining a logistic regression exposure model (with the COVID-19 status as response variable), and an outcome regression model (with the outcome of interest as response variable). For the binary outcomes, the outcome model was a logistic regression model, while 3-month mRS was an ordered logit regression model. We adjusted both exposure and outcome models for pre-specified potential confounders identified from previous literature as variables known to be associated with the outcome of interest, namely age, sex, NIHSS, ASPECTS, blood glucose, site of arterial occlusion, tandem lesion, time-to-treatment, center volume. Additional confounders specific for different outcomes were entered in the respective models, and are detailed in Figure 1 – Legend.

We expressed the results of the doubly robust estimation as odds ratio and confidence intervals. Given the potential clustering effect of patients from the same center, we included in each model the referring center as cluster level variable and calculated cluster-robust standard errors.

To account for missing data of the independent covariates, we performed multiple imputation by chained equation, generating ten imputed data sets.²⁴ The rate of missing data for each variable is reported in eTable 1 in Supplement. We performed analyses on each imputed dataset, then the estimates and the standard errors of the ten imputed analyses were combined using Rubin's Rules. We also conducted a sensitivity analysis including only patients with complete data (complete case analysis).

We performed a further analysis in the EVT group to evaluate the potential heterogeneity of a COVID-19 effect on outcomes in bridging vs. direct mechanical thrombectomy (DMT) patients. We assessed this by adding an interaction term between

COVID-19 status and IVT to the multivariable logistic regression outcome models adjusted for the same confounders as the main analysis. For this analysis, we reported the p-value of the interaction term and the effect of COVID-19 in the two groups (bridging and DMT).

All tests were two-sided and P-values < 0.05 were considered significant. Given that this was a retrospective study with an exploratory analysis, no correction for multiple outcome testing was applied. Also, a power calculation was not performed since previous data to estimate the expected effect of COVID-19 on the outcome of interest in revascularized stroke patients was lacking. We performed statistical analysis with R statistical software, version 4.0.3.

Results

We included 15128 patients from 105 participating centers. The median age was 71.6 (interquartile range [IQR] 13.8) years, 7767 (51.4%) were male, 5848 patients (38.7%) were treated with IVT only and 9280 patients (61.3%) with EVT (of whom 4841 had direct EVT and 4439 bridging). For participating patients, 1666 (11%) came from low-volume centers, 4743 (31.4%) from medium-volume centers, 5663 (37.4%) from high-volume centers and 3,056 (20.2%) from very high-volume centers.

Overall, 853 (5.6%) patients were diagnosed with COVID-19 and 14,275 patients (94.4%) were COVID-19-negative controls. SARS-CoV-2 infection was most frequently diagnosed at stroke onset (n=387, 45.5%), followed by diagnosis before stroke (n=324, 38.1%) and then diagnosis during hospital admission (n=139, 16.4%). With regard to COVID-19-related symptoms, 306 patients (36.0%) were asymptomatic and at home at stroke onset, 241 (28.4%) were symptomatic and at home, 266 (31.3%) were admitted to a hospital ward and 37 (4.3%) were in an intensive care unit.

Patients with COVID-19 were younger, more frequently male, had a higher prevalence of diabetes mellitus and dyslipidemia and a lower prevalence of current smoking. Stroke severity according to the NIHSS and admission blood glucose was higher in patients with COVID-19, while admission systolic blood pressure and ASPECTS were lower. Patients with COVID-19 more frequently had stroke of other determined cause and a lower proportion of stroke of undetermined etiology (Table 1).

In the IVT-only subgroup, COVID-19 patients and controls had the same differences in their baseline characteristics as in the whole cohort except for a non-significant difference in age, gender and dyslipidemia, while in the EVT subgroup; patients with COVID-19 additionally had a higher frequency of pre-admission treatment with oral anticoagulants (Table 1). Among patients treated with IVT (IVT-only or bridging) the LTSW-to-needle time was not different between COVID-19 patients and controls [179 minutes (IQR 125) vs. 176 minutes (IQR 125), respectively; p-value=0.667].

In the EVT subgroup, patients with COVID-19 had a higher rate of general anesthesia, a greater number of device passes, a worse final mTICI and lower rates of successful recanalization and first pass effect. We found no differences in symptoms-to-treatment times, treatment duration and symptoms-to-recanalization times (Table 2).

The univariable outcome analysis is showed in eTable 2 in the Supplement.

On the doubly robust adjusted outcome analysis on multiple imputed datasets, patients with COVID-19 showed a higher rate of SICH (OR 1.53; 95% CI 1.16–2.01), SSAH (OR 1.80; 95% CI 1.20–2.69) and SICH/SSAH (OR 1.56; 95% CI 1.23–1.99). They also had higher 24-hour (OR 2.47; 95% CI 1.58–3.86) and 3-month mortality rates (OR 1.88; 95% CI 1.52–2.33) and worse 3-month mRS shift (OR 1.42; 95% CI 1.26–1.60) and 3-month favorable outcomes (OR 1.48; 95% CI 1.22–1.78) (Figure 1 and eFigure 1). The analysis performed only on patients with a complete dataset gave similar results

(eTable 3 in the Supplement).

In patients with 24-hour mortality, patients with COVID-19 did not have a statistically significant higher rate of SICH/SSAH (OR 2.07; 95% CI 0.93–4.61). (eTable 4 in the Supplement).

The same outcome differences were found in the analysis stratified by treatment subgroup, except for the non-significant association with SSAH, SICH/SSAH and 24-hour mortality in the IVT-only group [(OR 0.80; 95% CI 0.26–2.47), (OR 1.48; 95% CI 0.94–2.33) and (OR 2.89; 95% CI 0.93–8.98), respectively] (Figure 1).

In the EVT subgroup, bridging-COVID-19 patients showed an increased risk of SICH, SSAH and SICH/SSAH, in contrast to DMT-COVID-19 patients who did not (Figure 2). However, the interaction analysis with IVT did not show statistically significant differences. The baseline features of bridging and DMT patients are displayed in eTable 5. No statistically significant differences were found when we analyzed the presence of hemorrhagic transformation according to ECASS II subgroups (eTable 6).

Discussion

To our knowledge, this is the largest study assessing safety and outcome of acute revascularization treatment in an international cohort of patients with AIS and COVID-19, and the first to investigate 3-month outcomes. We found that patients with AIS and COVID-19 receiving acute revascularization treatment had higher rates of SICH, SSAH, 24-hour and 3-month mortality and worse 3-month functional outcomes than AIS patients without COVID-19.

A previous large observational study showed that patients with COVID-19 probably have an increased risk of intracranial hemorrhage,²⁵ which is in line with the increased risk of ICH and SSAH after revascularization treatment for AIS. Endothelial dysfunction is likely a main mechanism of this observation.^{2,3} SARS-CoV2 binds to the

angiotensin-converting enzyme 2 (ACE2) receptor, causing ACE2 depletion, which in turn is associated with increased bradykinin levels promoting endothelial tight junction disruption, and therefore increased blood-brain barrier permeability. SARS-CoV2 infection was also shown to induce hyperfibrinolysis due to excessive plasmin-mediated fibrin cleavage.² Hyperfibrinolysis additionally promotes blood-brain barrier permeability in a bradykinin-dependent manner.²⁶ In addition, vasculitis and leukoencephalopathy similar to posterior reversible encephalopathy were described in anatomopathological studies of COVID-19 patients and associated with an excess of hemorrhagic lesion.²⁷ Other pathophysiological mechanisms such as increased systemic inflammation independent of SARS-CoV2 infection,²⁸ may also explain the higher rate of cerebral bleeding complications in our cohort. Of note, a higher risk of hemorrhagic transformation may also be present in patients with recent infections by other pathogens.²⁹

In the treatment subgroup analysis, both IVT-only and EVT patients had an increased risk of ICH, while only EVT patients showed an increased risk of SSAH. Indeed, the higher bleeding risks in EVT patients could also derive from the above-discussed COVID-19 pathophysiological mechanisms that can affect larger arteries, bringing more vulnerability for EVT procedure-related complications. A previous study has documented a vessel perforation rate of 5.5% in COVID-19 AIS patients,¹⁸ not different from that described in unselected AIS patients without COVID-19, although the definition of vessel perforation and other procedural complications are not uniformly defined in the current literature.³⁰ A higher number of device passes in our COVID-19 patients may result in higher degree of endothelial injury and bleeding risk. Finally, although the risk of SSAH in IVT-treated patients with COVID-19 did not seem to be

increased, the proportion of this complication was very rare in both groups, meaning insufficient power to make definite conclusions.

In line with our results, two previous small studies indicated an increased risk of bleeding complications after IVT and EVT in patients with COVID-19.^{13,15}

Given the increased risk of SICH in the IVT group, we also investigated whether bridging was associated with a higher risk of intracranial hemorrhage than DMT. In this subgroup analysis, patients undergoing DMT had a non-significant lower risk of hemorrhagic complications in comparison to bridging, despite a numerically lower risk. This finding is similar to non-COVID-19 patients undergoing EVT.³¹

We found an increased 24-hour mortality risk in revascularized patients with COVID-19, with more than a third of the mortality being explained by the higher intracranial hemorrhage risk. Poorer post-treatment reperfusion due to microvascular thrombo-inflammation or endotheliitis¹² and early stroke recurrence,⁹ are potential additional contributors for the worse short- and medium-term outcomes in patients with AIS and COVID-19.

Regarding larger arteries and their recanalization, previous studies have reported inconsistent data concerning EVT revascularization results in patients with COVID-19, with successful recanalization ranging from 56 to 100%^{9,12-14,17,19} and first pass effect from 0 to 35.6%.^{12,18} The procoagulant and proinflammatory states associated with COVID-19-related endothelial dysfunction² likely contribute to a higher clot burden and more difficult recanalization. In addition, small case series have described a high rate of clot fragmentation with distal embolization and repeated vessel occlusion in patients with COVID-19,^{16,17} phenomena that can also add to the poorer EVT results. Together with a myriad of multi-system complications associated with COVID-19 and prolonged hospital stay,^{6,11} the lower recanalization rate likely contributes to our findings of poorer

short- and medium-term outcomes in patients with COVID-19.

In our study, we did not find delays to revascularization treatment previously described in patients with AIS and COVID-19^{8,9,13} and proposed as a factor contributing to the worse clinical outcomes. The centers in the current study seem to have caught up with such delays during the long period of patient recruitment, which speaks to the resilience of many stroke systems as they learned to adapt to the COVID-19 surges, in contrast to the first months of the pandemic.

The strengths of our analysis are the large sample size with a low proportion of missing data, allowing for adjustments of multiple potential confounders. We enhanced representativeness by including patients from 30 countries across five continents. The use of the doubly robust statistical analyses may have helped to reduce multiple confounding biases.

Our study has limitations. Due to its retrospective design, registration bias cannot be excluded. It is likely that academic centers participated more in our study than primary stroke centers. Reporting bias, namely for outcomes, may have been influenced by the non-blinded assessment. As stated above, our clinical outcomes also depended on systemic COVID-19-related complications, not assessed in our study. Similarly, some COVID-19 patients were possibly treated outside the usual stroke care systems, with potential impact on outcome, and this information is lacking. We were not able to collect data on the precise virus variants, pandemic waves and vaccination status of our patients, which could have influenced our results. Presence of renal failure and collaterals, known to be associated with patients' outcomes, were not assessed, and therefore not included in our models. Finally, our study design did not allow direct conclusions to be made on the effectiveness of revascularization treatments in COVID-19 patients as we did not include an untreated comparison group.

Conclusion

In our international retrospective cohort study, patients with AIS and COVID-19 receiving revascularization treatment had higher rates of cerebral bleeding complications and worse short- and medium-term clinical outcomes than contemporary AIS controls without COVID-19. The relatively large margin of benefit of revascularization treatments, in particular of EVT, and the rather small absolute numbers of symptomatic hemorrhage in patients with AIS and COVID-19 make it likely that revascularization treatments remain beneficial for these patients. Therefore, we suggest that these treatments continue to be given as rapidly as possible to COVID-19 patients using the current treatment recommendations.

Table 1. Baseline, stroke characteristics and imaging data for the whole cohort, IVT-only and EVT subgroups

	Whole cohort					IVT-only					EVT			
Variables	Total (n=15128)	COVID-19 (n=853)	Controls (n=14275)	p-value		Total (n=5848)	COVID-19 (n=329)	Controls (n=5519)	p-value		Total (n=9280)	COVID-19 (n=524)	Controls (n=8756)	p-value
Demographics														
Age, years	71.6 (13.8)	69.7 (13.9)	71.7 (13.8)	<0.001		72.1 (14.0)	70.7 (13.8)	72.2 (14.0)	0.064		71.2 (13.7)	69 (13.9)	71.3 (13.7)	<0.001
Male gender	7767 (51.3%)	494 (57.9%)	7273 (51.0%)	<0.001		3222 (55.1%)	190 (57.8%)	3032 (55.0%)	0.349		4545 (49.0%)	304 (58.0%)	4241 (48.5%)	<0.001
Pre-stroke mRS				1.000					0.521					0.626
0-2	13341 (91.5%)	770 (91.5%)	12571 (91.3%)			4987 (88.2%)	285 (87.4%)	4702 (88.3%)			8354 (93.4%)	485 (94.0%)	7869 (93.3%)	
>2	1261 (8.4%)	72 (8.4%)	1189 (8.6%)			665 (11.8%)	41 (12.6%)	624 (11.7%)			596 (6.7%)	31 (6.0%)	565 (6.7%)	
Vascular risk factors														
Atrial fibrillation	4554 (30.2%)	244 (28.7%)	4310 (30.3%)	0.329		1140 (19.6%)	60 (18.3%)	1080 (19.6%)	0.603		3414 (37%)	184 (35.2%)	3230 (37.1%)	0.412
Heart failure	1781 (12.7%)	110 (13.4%)	1671 (12.6%)	0.572		475 (8.8%)	29 (8.9%)	446 (8.8%)	1.000		1306 (15.1%)	81 (16.2%)	1225 (15%)	0.496
Arterial hypertension	10666 (70.8%)	579 (67.9%)	10087 (71%)	0.057		4233 (72.6%)	231 (70.2%)	4002 (72.8%)	0.340		6433 (69.7%)	348 (66.4%)	6085 (69.8%)	0.106
Diabetes mellitus	3815 (25.4%)	284 (33.3%)	3531 (24.9%)	<0.001		1537 (26.4%)	108 (32.8%)	1429 (26%)	0.008		2278 (24.7%)	176 (33.6%)	2102 (24.1%)	<0.001
Dyslipidaemia	6955 (46.2%)	361 (42.3%)	6594 (46.5%)	0.020		2730 (46.9%)	145 (44.1%)	2585 (47.1%)	0.314		4225 (45.8%)	216 (41.2%)	4009 (46.1%)	0.033
Coronary artery disease	2435 (16.6%)	137 (17%)	2298 (16.6%)	0.823		941 (16.8%)	50 (16.5%)	891 (16.8%)	0.948		1494 (16.6%)	87 (17.3%)	1407 (16.5%)	0.691
Current smoking	3123 (21.1%)	130 (15.3%)	2993 (21.5%)	<0.001		1169 (20.4%)	36 (11%)	1133 (20.9%)	<0.001		1954 (21.6%)	94 (18%)	1860 (21.8%)	0.049
Active cancer	634 (4.9%)	34 (4.5%)	600 (4.9%)	0.672		215 (4.4%)	11 (3.8%)	204 (4.4%)	0.711		419 (5.2%)	23 (4.9%)	396 (5.2%)	0.890
Pre-stroke treatment														
Oral anticoagulants	2138 (14.2%)	137 (16.1%)	2001 (14.1%)	0.123		353 (6.1%)	17 (5.2%)	336 (6.1%)	0.560		1785 (19.4%)	120 (22.9%)	1665 (19.1%)	0.039
Antiplatelets	4437 (29.5%)	227 (26.7%)	4210 (29.6%)	0.070		2091 (35.9%)	102 (31%)	1989 (36.2%)	0.065		2346 (25.4%)	125 (24%)	2221 (25.5%)	0.453
Statins	4920 (33.9%)	256 (31.0%)	4664 (34.0%)	0.079		2016 (34.6%)	105 (32%)	1911 (34.8%)	0.335		2904 (33.3%)	151 (30.3%)	2753 (33.5%)	0.154
Stroke characteristics														
LTSW-to-door	180.6 (206.0)	178.5 (210.2)	180.7 (205.8)	0.770		131.7 (129.9)	133.8 (138.5)	131.5 (129.4)	0.775		213.6 (238.8)	208.3 (242.4)	213.9 (238.6)	0.622
Admission NIHSS	12 (6-18)	15 (8-20)	12 (6-18)	<0.001		7 (4-12)	9 (5-15)	6 (4-11)	<0.001		16 (10-20)	17 (12-21)	15 (10-20)	<0.001
Vascular territory				0.152					0.419					0.265
Anterior circulation	12566 (85.0%)	737 (86.7%)	11829 (84.9%)			4385 (78.8%)	267 (81.4%)	4118 (78.7%)			8181 (88.8%)	470 (90%)	7711 (88.7%)	
Posterior circulation	1724 (11.7%)	82 (9.7%)	1642 (11.8%)			908 (16.3%)	45 (13.7%)	863 (16.5%)			816 (8.9%)	37 (7.1%)	779 (9%)	
Multiple territories	488 (3.3%)	31 (3.6%)	457 (3.3%)			270 (4.8%)	16 (4.9%)	254 (4.8%)			218 (2.4%)	15 (2.9%)	203 (2.3%)	

	Whole cohort					IVT-only					EVT			
Variables	Total (n=15128)	COVID-19 (n=853)	Controls (n=14275)	p-value		Total (n=5848)	COVID-19 (n=329)	Controls (n=5519)	p-value		Total (n=9280)	COVID-19 (n=524)	Controls (n=8756)	p-value
Admission SBP	152.7 (27.2)	147 (25.4)	153 (27.3)	<0.001		157.7 (28)	151.2 (26.9)	158.1 (28)	<0.001		149.3 (26.1)	144.2 (24.1)	149.6 (26.2)	<0.001
Admission blood glucose	7.6 (3)	8.4 (3.8)	7.5 (3)	<0.001		7.5 (3.2)	8.5 (4.1)	7.5 (3.1)	<0.001		7.6 (2.9)	8.3 (3.5)	7.6 (2.9)	<0.001
Acute imaging														
ASPECTS*	10 (8-10)	9 (8-10)	10 (8-10)	<0.001		10 (9-10)	10 (8-10)	10 (9-10)	<0.001		9 (8-10)	9 (7-10)	9 (8-10)	0.008
Most proximal arterial occlusion				0.602					0.122					
None	2462 (19.2%)	133 (17.9%)	2329 (19.3%)			2462 (60.5%)	133 (56.8%)	2329 (60.7%)						0.155
Intracranial ICA	2039 (15.5%)	134 (17.8%)	1905 (15.3%)			159 (3.9%)	17 (7.3%)	142 (3.7%)			1880 (20.6%)	117 (22.5%)	1763 (20.5%)	
MCA M1	4808 (36.4%)	280 (37.2%)	4528 (36.4%)			329 (8.1%)	24 (10.3%)	305 (8%)			4479 (49.1%)	256 (49.3%)	4223 (49.1%)	
MCA M2-4	2323 (17.6%)	129 (17.1%)	2194 (17.6%)			622 (15.3%)	36 (15.4%)	586 (15.3%)			1701 (18.6%)	93 (17.9%)	1608 (18.7%)	
ACA A1-2	94 (0.7%)	5 (0.7%)	89 (0.7%)			43 (1.1%)	3 (1.3%)	40 (1%)			51 (0.6%)	2 (0.4%)	49 (0.6%)	
PCA P1-2	282 (2.1%)	16 (2.1%)	266 (2.1%)			148 (3.6%)	9 (3.9%)	139 (3.6%)			134 (1.5%)	7 (1.4%)	127 (1.5%)	
BA	656 (5%)	29 (3.9%)	627 (5%)			78 (1.9%)	5 (2.1%)	73 (1.9%)			578 (6.3%)	24 (4.6%)	554 (6.4%)	
V4	180 (1.4%)	8 (1.1%)	172 (1.4%)			68 (1.7%)	3 (1.3%)	65 (1.7%)			112 (1.2%)	5 (1%)	107 (1.2%)	
Other	277 (2.1%)	17 (2.3%)	260 (2.1%)			160 (3.9%)	4 (1.7%)	156 (4.1%)			117 (1.3%)	13 (2.5%)	104 (1.2%)	
Tandem lesion	2534 (19.2%)	104 (14.3%)	1459 (12.1%)	0.088		169 (4.6%)	13 (6.2%)	156 (4.5%)	0.305		1394 (15.3%)	91 (17.5%)	1303 (15.2%)	0.174
Stroke aetiology														
Large artery atherosclerosis	2783 (18.4%)	157 (18.4%)	2626 (18.4%)	<0.001		953 (16.3%)	51 (15.5%)	902 (16.3%)	<0.001		1830 (19.7%)	106 (20.2%)	1724 (19.7%)	<0.001
Cardioembolism	5996 (39.6%)	309 (36.2%)	5685 (39.8%)			1659 (28.4%)	88 (26.8%)	1571 (28.5%)			4337 (46.7%)	222 (42.4%)	4115 (49.0%)	
Small vessel disease	671 (4.4%)	33 (3.9%)	638 (4.5%)			671 (11.5%)	33 (10.0%)	638 (11.6%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	
Dissection	288 (1.9%)	15 (1.8%)	273 (1.9%)			77 (1.3%)	5 (1.5%)	72 (1.3%)			211 (2.3%)	10 (1.9%)	201 (2.3%)	
Other determined aetiology	762 (5%)	118 (13.8%)	644 (4.5%)			347 (5.9%)	51 (15.5%)	296 (5.4%)			415 (4.5%)	67 (12.8%)	348 (4%)	
Undetermined	4628 (30.6%)	220 (25.8%)	4408 (30.9%)			2141 (36.6%)	101 (30.7%)	2040 (37%)			2487 (26.8%)	119 (22.7%)	2368 (27%)	

Values are presented as median (interquartile range) or as numbers (proportions). IVT, intravenous thrombolysis; EVT, endovascular treatment; mRS, modified Rankin scale; LTSW, last time seen well; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; ASPECTS, Alberta Stroke Program Early CT score; ICA, internal carotid artery; M1/2/3/3, first, second and third segments of middle cerebral artery; ACA1/2, first and second segments of anterior cerebral artery; PCA, first and second segments of posterior cerebral artery BA, basilar artery; V4, fourth segment of vertebral artery.

*in posterior circulation stroke, it corresponds to Posterior Circulation ASPECTS

Table 2. Treatment characteristics of EVT patients

Variables	Total (n=9280)	COVID-19 (n=524)	Controls (n=8756)	p-value
Revascularization treatment				0.024
Direct EVT	4841 (52.2%)	299 (57.1%)	4542 (51.9%)	
Bridging	4439 (47.8%)	225 (42.9%)	4214 (48.1%)	
LTSW-to-puncture	352.5 (251.4)	352.6 (254.6)	352.5 (251.2)	0.998
General anesthesia	3342 (36.4%)	236 (45.2%)	3106 (35.9%)	<0.001
Final mTICI score				<0.001
0	688 (7.5%)	46 (8.8%)	642 (7.4%)	
1	185 (2.0%)	21 (4.0%)	164 (1.9%)	
2a	482 (5.2%)	40 (7.6%)	442 (5.1%)	
2b	2322 (25.3%)	131 (25.0%)	2191 (25.3%)	
2c	993 (10.8%)	65 (12.4%)	928 (10.7%)	
3	4510 (49.1%)	221 (42.2%)	4289 (49.5%)	
Successful recanalization (mTICI ≥2b)	7825 (85.2%)	417 (79.6%)	7408 (85.6%)	<0.001
First pass effect	2549 (28%)	124 (23.7%)	2425 (28.3%)	0.026
Number of device passes				0.032
0	456 (5.1%)	17 (3.3%)	439 (5.2%)	
1	3939 (44.1%)	215 (41.3%)	3724 (44.3%)	
2	2023 (22.7%)	115 (22.1%)	1908 (22.7%)	
3	1256 (14.1%)	84 (16.1%)	1172 (13.9%)	
>3	1253 (14%)	90 (17.3%)	1163 (13.8%)	
LTSW-to-reperfusion	401.3 (251.5)	400 (256.2)	401.4 (251.3)	0.905
Procedure duration	51.4 (41.2)	49.8 (36.4)	51.5 (41.5)	0.313

Values are presented as median (interquartile range) or as numbers (proportions). IVT, intravenous thrombolysis; EVT, endovascular treatment; LTSW, Last time seen well; mTICI, modified treatment in cerebral infarction

Figures legend

Figure 1.

Title

Forest plot of intracranial bleeding complications, mortality and disability comparing patients with COVID-19 and controls of the whole cohort and IVT-only and EVT subgroups

Legend

OR, Odds ratio; CI, Confidence Interval; IVT, Intravenous thrombolysis; EVT, Endovascular treatment; SICH, Symptomatic intracerebral hemorrhage; SSAH, Symptomatic subarachnoid hemorrhage; mRS, modified Rankin Scale.

*Or mRS equal to pre-stroke mRS, if > 2

All models were adjusted for age, sex, NIHSS, ASPECTS, blood glucose, site of arterial occlusion, tandem lesion, time-to-treatment, center volume. SICH, SAH and SICH/SAH models were also adjusted for systolic blood pressure and previous antithrombotic therapy. Mortality and mRS models were also adjusted for pre-stroke mRS, cancer and coronary heart disease. Models on the entire cohort were also adjusted for type of revascularization treatment (IVT-only vs. EVT). Models on the EVT cohort were also adjusted for IVT, number of device passes and successful revascularization.




Figure 2


Title

Forest plot of intracranial bleeding complications, mortality and disability comparing patients with COVID-19 and controls in Bridging and direct mechanical thrombectomy treatments

Legend

OR, Odds ratio; CI, Confidence Interval; MT, Mechanical thrombectomy; SICH, Symptomatic intracerebral hemorrhage; SSAH, Symptomatic subarachnoid hemorrhage; mRS, modified Rankin Scale.

*Or mRS equal to pre-stroke mRS, if > 2



Conflict of interest:

Roman Herzig: Research grants from the Ministry of Health of the Czech Republic (grant number DRO – UHHK 00179906) and Charles University, Czech Republic (grant number PROGRES Q40).

Christian Nolte: Research grants from German Ministry of Research and Education, German Center for Neurodegenerative Diseases, German Center for cardiovascular Research. Speaker and/or advisory fees from Abbott, Alexion, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and Pfizer Pharma.

Stavropoula Tjoumakaris: Advisory fees from Medtronic and MicroVention.

Jiangyong Min: Advisory fees from Medtronic and Abbott

Muhib-A Khan: Research grants from National Institute of Health, Spectrum Health-Michigan State University Research Alliance and Genentech for research.

Patrik Michel: Research grants from the Swiss National Science Foundation and Swiss Heart Foundation.

All the other authors do report no conflict of interest.

WNL-2022-201390_sup -- <http://links.lww.com/WNL/C428>

References

1. Mao L, Jin H, Wang M, et al. Neurologic manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.* 2020;77:683–690.
2. Sashindranath M, Nandurkar HH. Endothelial Dysfunction in the Brain: Setting the Stage for Stroke and Other Cerebrovascular Complications of COVID-19. *Stroke.* 2021; 2021;52(5):1895-1904
3. Sagris D, Papanikolaou A, Kvernland A, et al. COVID-19 and ischemic stroke. *Eur J Neurol.* 2021;28(11):3826-3836.
4. Mbonde AA, O'Carroll CB, Grill MF, Zhang N, Butterfield R, Demaerschalk BM. Stroke Features, Risk Factors, and Pathophysiology in SARS-CoV-2-Infected Patients. *Mayo Clin Proc Innov Qual Outcomes.* 2022;6(2):156-165.
5. Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. *Stroke.* 2020;5:e254-e258.
6. Dhamoon MS, Thaler A, Gururangan K, et al. Acute Cerebrovascular Events With COVID-19 Infection. *Stroke.* 2021;52:48-56.
7. Perry RJ, Smith CJ, Roffe C, et al. Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study. *J Neurol Neurosurg Psychiatry.* 2021;92:242-248.

8. Srivastava PK, Zhang S, Xian Y, et al. Acute Ischemic Stroke in Patients With COVID-19: An Analysis From Get With The Guidelines-Stroke. *Stroke*. 2021 May;52(5):1826-1829.
9. Fuentes B, Alonso de Leciñana M, García-Madrona S, et al. Stroke Acute Management and Outcomes During the COVID-19 Outbreak: A Cohort Study From the Madrid Stroke Network. *Stroke*. 2021;52:552-562.
10. Strambo D, De Marchis GM, Bonati LH, et al; Swiss Stroke Registry Investigators. Ischemic stroke in COVID-19 patients: Mechanisms, treatment, and outcomes in a consecutive Swiss Stroke Registry analysis. *Eur J Neurol*. 2022;29:732-743.
11. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020;324:782-793.
12. Escalard S, Maier B, Redjem H, et al. Treatment of Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience From Paris. *Stroke*. 2020;51:2540-2543.
13. Pezzini A, Grassi M, Silvestrelli G, et al. Impact of SARS-CoV-2 on reperfusion therapies for acute ischemic stroke in Lombardy, Italy: the STROKCOVID network. *J Neurol*. 2021;268:3561-3568.
14. Cappellari M, Zini A, Sangalli D, et al. Thrombolysis and bridging therapy in patients with acute ischaemic stroke and Covid-19. *Eur J Neurol*. 2020;27:2641-2645.
15. Sasanejad P, Afshar Hezarkhani L, Arsang-Jang S, E, et al. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative. *J Stroke Cerebrovasc Dis*. 2021;30:106121.

16. Pop R, Hasiu A, Bolognini F, et al. Stroke Thrombectomy in Patients with COVID-19: Initial Experience in 13 Cases. *AJNR Am J Neuroradiol*. 2020;41:2012-2016.
17. Wang A, Mandigo GK, Yim PD, Meyers PM, Lavine SD. Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. *J Neurointerv Surg*. 2020;12:648-653.
18. Cagnazzo F, Piotin M, Escalard S, et al. European Multicenter Study of ET-COVID-19. *Stroke*. 2021;52:31-39.
19. European Centre for Disease Prevention and Control. Surveillance definitions for COVID-19. <https://www.ecdc.europa.eu/en/covid-19/surveillance/surveillance-definitions>.
20. WHO COVID-19 Case definition. https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2.
21. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. *Lancet*. 1998 17;352:1245-51.
22. Zaidat OO, Castonguay AC, Linfante I, et al. First Pass Effect: A New Measure for Stroke Thrombectomy Devices. *Stroke*. 2018;49:660-666.
23. Zetterqvist J, Sjölander A. Doubly Robust Estimation with the R Package drgee. *Epidemiologic Methods*. 2015;4:69-86.
24. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *J Stat Softw*. 2011;45:1-67.
25. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-

- 19 Vaccine in a Nationwide Setting. *N Engl J Med*. 2021;385:1078-1090.
26. Marcos-Contreras OA, Martinez de Lizarrondo S, Bardou I, et al. Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. *Blood*. 2016;128:2423–2434.
27. Hernández-Fernández F, Sandoval Valencia H, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. *Brain*. 2020;143:3089-3103.
28. Tiainen M, Meretoja A, Strbian D, et al; Helsinki Stroke Thrombolysis Registry Group. Body temperature, blood infection parameters, and outcome of thrombolysis-treated ischemic stroke patients. *Int J Stroke*. 2013;8:632–8.
29. Consoli D, Vidale S, Arnaboldi M, et al. Infections and Chlamydia pneumoniae antibodies influence the functional outcome in thrombolysed strokes. *J Neurol Sci*. 2017;381:95–99.
30. Maslias E, Nannoni S, Ricciardi F, et al. Procedural Complications During Early Versus Late Endovascular Treatment in Acute Stroke: Frequency and Clinical Impact. *Stroke*. 2021;53:1079–1082.
31. Fischer, U; on behalf of the Improving Reperfusion strategies in Ischemic Stroke (IRIS) working group investigators, Direct mechanical thrombectomy versus bridging therapy – cumulative study-level meta-analysis of the DIRECT-MT, MR CLEAN-NOIV, DEVT, SKIP AND SWIFT-DIRECT Randomized Clinical Trials. *Eur Stroke J* 2021;6(1S):514.

Neurology®

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry

João Pedro Marto, Davide Strambo, George Ntaios, et al.

Neurology published online November 9, 2022

DOI 10.1212/WNL.0000000000201537

This information is current as of November 9, 2022

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/early/2022/11/09/WNL.0000000000201537.full
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Cerebrovascular disease/Stroke http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke COVID-19 http://n.neurology.org/cgi/collection/covid_19
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

